What is DaShenLin Pharmaceutical Group Co FCF Margin %?
DaShenLin Pharmaceutical Group CoSHSE:603233 95 FCF Margin % is 12.22% as of Mar. 2026, which is 108% above its 10-year median of 5.88. GuruFocus rates SHSE:603233 with a GF Score™ of 95/100 and a GF Value™ of ¥18.69 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 666 Healthcare Providers & Services companies, DaShenLin Pharmaceutical Group Co ranks better than 84.23% on this metric.
The historical rank and industry rank for DaShenLin Pharmaceutical Group Co's FCF Margin % or its related term are showing as below:
SHSE:603233'
s FCF Margin % Range Over the Past 10 Years
Min: -0.28 Med: 5.88 Max: 17.69
Current: 14.67
During the past 13 years, the highest FCF Margin % of DaShenLin Pharmaceutical Group Co was 17.69%. The lowest was -0.28%. And the median was 5.88%.
SHSE:603233's FCF Margin % is ranked better than 84.23% of 666
companies
in the Healthcare Providers & Services industry
Industry Median: 3.22
vs SHSE:603233: 14.67
DaShenLin Pharmaceutical Group Co FCF Margin % Related Terms
DaShenLin Pharmaceutical Group Co FCF Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DaShenLin Pharmaceutical Group Co FCF Margin % Chart
DaShenLin Pharmaceutical Group Co FCF Margin % Competitor Comparison
For the Pharmaceutical Retailers subindustry, DaShenLin Pharmaceutical Group Co's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DaShenLin Pharmaceutical Group Co FCF Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, DaShenLin Pharmaceutical Group Co's FCF Margin % distribution charts can be found below:
* The bar in red indicates where DaShenLin Pharmaceutical Group Co's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DaShenLin Pharmaceutical Group Co (SHSE:603233) has a FCF Margin % of 12.22% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on DaShenLin Pharmaceutical Group Co and its competitors. This is 108% above median its historical median of 5.88. According to the industry distribution chart, DaShenLin Pharmaceutical Group Co ranks #105 out of 666 companies in the Healthcare Providers & Services industry, placing it in the top 15.8%.
Is DaShenLin Pharmaceutical Group Co's FCF Margin % too high?
DaShenLin Pharmaceutical Group Co's current FCF Margin % of 12.22% is 108% above median its 10-year median of 5.88. The Healthcare Providers & Services industry median FCF Margin % is 3.22. DaShenLin Pharmaceutical Group Co's value of 12.22% is 279.5% above this industry median. Based on the distribution chart, DaShenLin Pharmaceutical Group Co ranks #105 out of 666 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, DaShenLin Pharmaceutical Group Co has a GF Score™ of 95/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does DaShenLin Pharmaceutical Group Co's FCF Margin % compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, DaShenLin Pharmaceutical Group Co ranks #105 out of 666 companies for FCF Margin %. This places DaShenLin Pharmaceutical Group Co in the top 16% of its industry — outperforming the majority of peers. The industry median FCF Margin % is 3.22. DaShenLin Pharmaceutical Group Co's value of 12.22% is 279.5% above this benchmark. While the company's 10-year median is 5.88 vs. the industry median of 3.22, DaShenLin Pharmaceutical Group Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Healthcare Providers & Services company?
The median FCF Margin % among Healthcare Providers & Services companies is 3.22, based on 666 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. DaShenLin Pharmaceutical Group Co's current FCF Margin % of 12.22% is 279.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on DaShenLin Pharmaceutical Group Co and its competitors. For the Healthcare Providers & Services industry, the median FCF Margin % is 3.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DaShenLin Pharmaceutical Group Co's current FCF Margin % is 12.22%, which is 108% above median its own 10-year median of 5.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DaShenLin Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, DaShenLin Pharmaceutical Group Co (SHSE:603233) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥18.69, compared to a current price of ¥15.48 — trading 17.2% below its estimated fair value. The current FCF Margin % is 12.22%, which is 108% above median its 10-year median of 5.88 and 279.5% above the Healthcare Providers & Services industry median of 3.22. DaShenLin Pharmaceutical Group Co's overall GF Score™ is 95/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For DaShenLin Pharmaceutical Group Co (SHSE:603233), the current FCF Margin % is 12.22% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is DaShenLin Pharmaceutical Group Co (SHSE:603233) Overvalued in 2026?
Based on GuruFocus' analysis, DaShenLin Pharmaceutical Group Co stock appears to be undervalued.
The current stock price of ¥15.48 is trading 17.2% below its estimated GF Value™ of ¥18.69.
GuruFocus considers DaShenLin Pharmaceutical Group Co to be Modestly Undervalued.
Key valuation signals for SHSE:603233:
FCF Margin %: 12.22% (108% above median its 10-year median of 5.88)
GF Value™: ¥18.69 vs. price of ¥15.48 (17.2% below fair value)
Industry Position: 279.5% above the Healthcare Providers & Services median (#105 of 666)
No single metric tells the full story. See the SHSE:603233 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
DaShenLin Pharmaceutical Group Co Business Description
DaShenLin Pharmaceutical Group Co Ltd is engaged in the pharmaceutical manufacturing, retail, and wholesale business. The company is based on the development of the pharmacy chain. It primarily offers Chinese herbal medicine such as antibiotics and biochemical drugs. The business activities are geographically carried out through China.
95GF Score
Get the complete analysis for SHSE:603233
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603233 has been successfully added to your 
